A carregar...
Ambrisentan for the treatment of pulmonary arterial hypertension
Ambrisentan is an endothelin receptor antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH). Endothelin (ET) is a potent vasoconstrictor with mitogenic, hypertrophic and pro-inflammatory properties that is upregulated in pulmonary hypertensive diseases. T...
Na minha lista:
Main Authors: | , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Dove Medical Press
2009
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2761178/ https://ncbi.nlm.nih.gov/pubmed/19920913 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|